Introduction & Objective: The GIP/GLP-1 receptor agonist tirzepatide (TZP) achieved body weight loss near 20% in Chinese adults with overweight (24 kg/m2≤BMI<28 kg/m2) with at least one weight-related comorbidity or obesity (BMI ≥28 kg/m2) in SURMOUNT-CN. Weight regain post-TZP cessation in Chinese population is unknown. Hence, we examined the changes in body weight (BW) and waist circumference (WC) after TZP cessation in the trial extension.

Methods: SURMOUNT-CN randomized (1:1:1) Chinese adults (n=210) with a BMI of ≥28 kg/m2, or ≥24 kg/m2 and weight-related comorbidities, excluding diabetes, to receive TZP 10 mg / 15 mg / placebo (PBO) for 52 weeks. Our study enrolled those who completed 52 weeks of TZP / PBO and followed them for 6 months. Participants with neither anti-obesity medication (AOM) nor bariatric procedures during follow-up (FU) were eligible analysis population (EAP). Changes of BW and WC at 3- and 6-month FU (±6 weeks) were analyzed using descriptive statistics.

Results: Among 160 enrolled, 152 (TZP 10 mg: 57; TZP 15 mg: 51; PBO: 44) constituted EAP, excluding 8 for AOM use. For EAP, from trial baseline to week 52, TZP showed marked BW and WC reduction: -15.33% (SD: 8.04%) and -12.82 cm (SD: 6.86) for 10 mg, -19.88% (SD: 8.78%) and -15.59 cm (SD: 7.26) for 15 mg, against PBO’s -3.80% (SD: 6.08%) and -3.70 cm (SD: 4.51). From week 52 to 6-month FU, BW and WC increased for TZP 10 mg (9.06% [SD: 7.41%], 2.89 cm [SD: 7.48]), and 15 mg (12.33% [SD: 9.88%], 5.53 cm [SD: 6.52]), while PBO showed slight change (1.83% [SD: 5.17%] and -0.52 cm [SD: 5.58]). Overall, from trial baseline to 6-month FU, changes in BW and WC with TZP 10 mg, 15 mg and PBO were -8.74% (SD: 6.93%) and -10.50 cm (SD: 8.07), -10.57% (SD: 10.23%) and -10.61 cm (SD: 9.29), -2.47% (SD: 7.03%) and -4.02 cm (SD: 7.21).

Conclusion: While over 50% of net weight loss was maintained after 6 months of TZP cessation, the increase in BW and WC from drug cessation supports continued weight management in clinical practice.

Disclosure

Y. Chen: None. C. Chen: None. L. Zhao: None. Y. Lu: None. X. Fan: None. L. Xu: None. Y. Wang: Employee; Eli Lilly and Company. Y. Dong: Employee; Eli Lilly and Company. Y. Li: None. J. Xu: None. S. Si: None. X. Zhang: Employee; Eli Lilly and Company. X. Li: None.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.